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ABSTRACT 
The single greatest risk factor for neurodegenerative diseases is aging. Aging of 
cells such as microglia in the nervous system has an impact not only on the ability of 
those cells to function but also on cells they interact with. We have developed a 
model microglia system that recapitulates the dystrophic/senescent phenotype and 
we have combined this with the study of β-amyloid processing. The model is based 
on the observation that aged microglia have increased iron content. By overloading a 
human microglial cell line with iron we were able to change the secretory profile of 
the microglia. When combining these senescent microglia with SH-SY5Y cells we 
noted an increase in extracellular β-amyloid. The increased levels of β-amyloid were 
due to a decrease in the release of insulin-degrading enzyme by the model 
senescent microglia. Further analysis revealed that the senescent microglia showed 
both decreased autophagy and increased ER stress. These studies demonstrate the 
potential impact of an aging microglial population in terms of β-amyloid produced by 
neurons which could play a causal role in diseases like Alzheimer’s disease. Our 
results also further develop the potential utility of an in vitro model of senescent 
microglia for the study of brain aging and neurodegenerative disease. 
 
Key words:  beta-amyloid, APP, microglia, ER stress, autophagy, insulin degrading 
enzyme 
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INTRODUCTION  
There is overwhelming evidence for the importance of aging to the aetiology of 
neurodegenerative diseases1. Conditions like Alzheimer’s disease (AD) increase in 
frequency as we age 2. There are numerous diseases, including inherited forms of 
AD and prion diseases where dominant inherited mutations lead to 
neurodegeneration, but only when the carrier passes a certain age 3, 4. Clearly 
understanding how the brain changes with age and how such changes result in the 
development of diseases involving neuronal dysfunction and loss is essential for 
understanding neurodegeneration. Therefore it is quite surprising that very few 
studies incorporate any aspect of the aging brain in their models. There is an 
inherent difficulty in including an aspect of aging in the development of a model of 
neurodegeneration because of the time requirement; eg. animal models would have 
to utilize animals that are towards the end of their life span 5. In vitro models have 
even greater hurdles because such models are inherently short term 6, 7. Therefore a 
potential alternative is to develop a method to induce a phenotypic change 
equivalent to that seen in cells from an aged brain. 
 
Microglia are important cells in the brain that maintain neuronal well-being 8. There is 
a plethora of information suggesting that microglia may participate in changes in the 
brain associated with neurodegenerative diseases 9-15. These changes mostly relate 
to an altered secretory profile wherein the molecules released either result in 
reduced protection of neurons or an increase in proinflammatory or toxic molecules 
such as cytokines or reactive oxygen species 16. Microglia change phenotype in this 
way with age and aged microglia are frequently described as dystrophic 17. Microglia 
may develop a senescent-associated secretory phenotype (SASP) 18-20. While SASP 
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is mostly associated with a study of molecular changes in cells, the dystrophic 
phenotype has largely been assigned on the basis of morphological changes. While 
both phenotypes are age associated they have been rarely used in conjunction to 
describe aged microglia.  Understanding how microglia could enter such a 
phenotypic state and the potential of microglia to alter neuronal activity as a result is 
of considerable importance. Phenotypically, dystrophic microglia express increased 
levels of the iron storage protein ferritin 21, 22, which is a directly related to the 
increased levels of iron stored by them 23. Increased iron levels in the brain are 
associated with both aging and patients with a variety of neurodegenerative diseases 
including AD and Parkinson’s disease 24-27. 
 
Dystrophic/senescent microglia are present in the brains of patients with AD 20, 28. 
However, while their presence has been shown, any causative role is unknown. AD 
is mostly associated with the deposition of protein aggregates which include β-
amyloid in the form of plaques and tau in the form of paired-helical filaments or 
tangles 29, 30. Microglia secrete enzymes that are able to degrade beta-amyloid such 
as insulin-degrading enzyme (IDE) and neprilysin 31, 32. There have also been reports 
suggesting neuronal loss in AD may come from activation of microglia as a result of 
interaction with beta-amyloid deposits 33, 34. While there is considerable interest in 
microglia in terms of the pathology of AD, the impact of microglial senescence on the 
aetiology of the disease is unknown. 
 
In this work we examine a new model of senescent microglia based on the 
observation that overloading microglia with iron forces them into a senescent-like 
phenotype. Combining these microglia with a neuronal cell line allowed us to 
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investigate how the change in phenotype alters the generation of β-amyloid. 
Following treatment of SH-SY5Y cells with conditioned medium from dystrophic 
microglia, there is an increase in β-amyloid present in the medium due to a decrease 
in the secretion of IDE. We have linked this change in IDE release to increased ER 
stress in microglia induced by the iron overload. The results cast light on the possible 
mechanism by which brain aging causes increased deposition of β-amyloid which 
could lead to AD.  
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RESULTS 
Phenotype of iron-fed microglia 
We used a human microglia cell line as the basis of our investigation. This line was 
chosen because it allowed the generation of sufficient cells for experiments and also 
because it maintained the species match for experiments involving β-amyloid 
generated by the human SH-SY5Y neuroblastoma cell line. As aged dystrophic 
microglia show high levels of stored iron we hypothesized that the dystrophic 
phenotype might be a consequence of high retention of iron 22. Iron (particularly 
Fe(II)) causes damage to macromolecules and increased storage could be sufficient 
to induce changes seen in the dystrophic phenotype. For this reason we grew the 
human microglial cell line in 500 µM ferric ammonium citrate for at least two weeks. 
 
In microglial cells grown in medium with high iron (iron-fed) we observed 
morphological changes similar to dystrophic microglia 17. Under normal culture 
conditions (Figure 1A) microglia cells showed a small cell body with multiple 
projections and frequent ramification. In contrast iron-fed microglia (Figure 1B) 
showed no ramification and little to no projections. In many cases the microglia 
became amoeboid.  
 
We verified that iron storage had occurred by three methods. First we used Perl’s 
stain to identify iron deposits in the cells. As can be seen in Figure 2 control 
microglial cells (Figure 2A) had little to no deposits while iron-fed microglia showed 
large numbers of iron deposits in blue (Figure 2B). This demonstrates that iron-fed 
microglia store considerably more iron than the untreated control. Similarly, levels of 
ferritin are considered to reflect the levels of stored iron in cells. We measured the 
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levels of ferritin in control and iron-fed microglia by western blot and immune 
detection. The levels of ferritin in iron-fed microglia were much higher than in 
controls (Figure 2C and 2D). Lastly, we directly measured the levels of total iron in 
the microglia using a commercial kit. Iron-fed microglia showed considerably higher 
levels of total iron (Figure 2E). 
 
Treatment of the microglial cell line with high concentrations of iron may have 
adversely affected their viability in culture. To control for this we measured their 
proliferation when compared to controls using a BrdU incorportation assay. Control 
and iron-fed human microglia were plated at a range of densities and the 
incorporation of BrdU assessed using an ELISA assay (Figure 3). Regardless of 
plating density, the iron-fed microglia showed no significant difference in BrdU 
incorporation suggesting that the iron-fed microglia maintained the same proliferation 
rate as the untreated controls. 
 
Alteration in the secretory profile is an indication of a potential senescent phenotype 
in cells 35. Microglia are known to show increased pro-inflammatory cytokine 
secretion with age 18. Therefore we assessed a panel or cytokines associated with 
pro-inflammatory responses. Conditioned medium from control and iron-fed microglia 
were collected and normalized in relation to the protein content of the microglia used 
to conditioned the medium. The cytokines measured were IFN-γ, IL-10, IL-12p70, IL-
13, IL-1β, IL-2, IL-4, IL-6, IL-8 and TNF-α (Table 1). Some of the cytokines tested 
could not be detected while other showed no changes. However, a number of the 
cytokines measured showed significant elevation. These included IL-1β, IL-6 and IL-
8. The other measureable cytokines showed no changes (IL-2, IL10, IL13, TNFα). 
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This selective change in cytokines suggests a change in microglial phenotype similar 
to that suggested for aged microglia. 
 
We also assessed other reported markers for aged/senescent microglia. It has been 
suggested that during the aging process microglia show reduced secretion of 
glutamate 36. We used a commercial glutamate assay kit to measure glutamate 
released into culture by control and iron-fed microglia. Figure 4A shows that iron-fed 
microglia released significantly less glutamate than control microglia. In addition we 
measured two known markers for aged microglia. These included KV1.3 a microglial 
potassium channel and SIRT-1 (sirtuin-1) a deacetylase. KV1.3 has been shown to 
be altered in aged mice and to play a role in the release of cytokines 37, 38. SIRT-1 
has been shown to be decreased in aged microglia and this may contribute to 
cognitive decline and neurodegeneration 39.We used western blotting and specific 
antibodies to detect these proteins in extracts from control and iron fed microglia 
(Figure 4B-D). Iron-fed microglia showed a significant increase in the level of 
expression of KV1.3 but a significant decrease in expression of SIRT-1. These 
results are consistent with the suggestion that iron-fed microglia demonstrate a 
change in phenotype similar to dystrophic or senescent microglia in vivo. We are 
therefore confident that our iron-fed human microglia represent a robust in vitro 
model of senescent microglia. 
 
Effect of Microglial Conditioned Medium on APP Metabolism in SH-SY5Y 
Neuronal Cells 
Alzheimer’s disease is associated with the deposition of abnormal proteins including 
β-amyloid. The rate of formation of β-amyloid depends upon the metabolism of its 
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precursor, APP and the relative activity of the two secretase pathways that either 
degrade APP to form β-amyloid (β-secretase dependent) or P3 (α-secretase 
dependent). In either pathway the end result is the release of an APP fragment by 
the gamma-secretase complex. However, the rate of formation of these products 
could be influenced by the level of expression of APP and the enzymes ADAM10 (α-
secretase) and BACE-1 (β-secretase). The model we used to study the levels of 
these proteins was the human neuroblastoma cell line, SH-SY5Y. Conditioned 
medium was prepared from control and iron-fed microglia and applied to SH-SY5Y 
cells for 24 h. After that time the SH-SY5Y cells were assessed for the expression of 
these proteins by western blot and immunodetection with specific antibodies. As 
shown in Figure 5 treatment of SH-SY5Y cells with microglial conditioned medium 
had no significant effect on the expression of either APP or BACE-1. In contrast, 
conditioned medium from iron-fed microglia but not control microglia had a significant 
effect reducing the levels of ADAM10 protein by SH-SY5Y cells. 
We investigated the consequences of altered ADAM10 expression through a variety 
of assays. First we used a dual luciferase assay of APP cleavage to assess if there 
is any change in the rate of formation of the AICD fragment of APP. In this system, a 
GAL4 DNA binding tag is attached to the C-terminal of the APP protein. The assay is 
dependent on the cleavage of this tagged form of APP and the release of the tag 
which is then able to induce luciferase expression by binding to the luciferase 
reporter. Our previous work has demonstrated that in SH-SY5Y cells, the 
predominant cleavage of this tagged APP is sequential via beta-secretase and then 
gamma secretase to release the tagged AICD fragment40.  SH-SY5Y cells were 
transiently transfected with the APP expression plasmid, the luciferase reporter 
plasmid and a third Renilla luciferase construct that controls for transfection 
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efficiency and differences in cell number. The transfected cells were then treated 
with conditioned medium from control and iron-fed microglia for 24 h. Luciferase 
activity was then measured in extracts from the cells and compared to transfected 
controls that were treated only with serum free medium. The result showed that both 
medium from control and iron-fed microglia had a significant effect on the luciferase 
levels detected (Figure 6A). This suggests that AICD fragment formation is greatly 
reduced by microglia conditioned medium. However, there was no significant 
difference between control and iron fed conditioned medium. This implies that the 
change in ADAM10 expression induced by iron-fed microglia had no effect on rates 
of APP cleavage. 
We then measured the activity of the ADAM10 promoter using a reporter construct 
containing the promoter for human ADAM10. The SH-SY5Y cells were similarly 
transiently transfected with this construct and the Renilla control. The transfected 
cells were then treated with conditioned medium from control and iron-fed microglia 
for 24 h. The result showed that neither medium from control nor iron-fed had any 
significant effect on the luciferase levels detected (Figure 6B). This implies that the 
change in ADAM10 protein expression we observed was not a consequence of 
altered transcription of ADAM10 mRNA. 
Following from this we wished to confirm whether altered ADAM10 expression 
resulted in altered ADAM10 activity. We therefore used a FRET-based assay to 
assess ADAM10 activity in extracts of SH-SY5Y cells treated with conditioned 
medium from control and iron-fed microglia. The assay measured the cleavage of a 
tagged peptide substrate. After 24 h of treatment with conditioned medium extracts 
from the treated SH-SY5Y cells were applied to the assay and the level of cleavage 
measured. The results showed that there was no significant difference in ADAM10 
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activity in SH-SY5Y cells treated with conditioned medium from microglia (Figure 
6C). The implication of this is that, despite the change in ADAM10 protein 
expression, there is no consequence of this in terms of measurable activity. 
Lastly, as we have observed reduced protein expression of ADAM10 we looked for 
an alternative explanation for the change. It is known that ADAM10 translation can 
be down-regulated through the activity of the translation suppressor, FMRP (Fragile-
x mental retardation protein)41. We assessed the expression of FMRP in SH-SY5Y 
cells by western blot. SH-SY5Y cells were treated with conditioned medium from 
control and iron-fed microglia for 24 h. Protein extracts were then prepared and the 
western blot procedure carried out. The levels of FMRP were assessed using a 
specific antibody. The results showed a significant increase in FMRP in SH-SY5Y 
cells treated with conditioned medium from iron-fed microglia but not from control 
microglia (Figure 6D & E). What this points to is that conditioned medium from iron-
fed microglia increases the expression of the translation inhibitor FMRP known to 
regulate the translation of ADAM10. 
The cleavage of APP causes release of β-amyloid from neuronal cells such as SH-
SY5Y cells. The released β-amyloid can be detected in cell culture medium. We 
used a very sensitive MSD immunoassay to measure β-amyloid released into the 
serum free cell culture medium by SH-SY5Y cells. Treatment of SH-SY5Y cells with 
conditioned medium from control microglia for 24 h resulted in a large and significant 
reduction in  β-amyloid (both Aβ1-40 and Aβ1-42) that could be detected in the medium 
(Figure 7A). In comparison SH-SY5Y cells treated with conditioned medium from 
iron-fed microglia had a significantly reduced effect on the levels of β-amyloid (Figure 
7A-B). The implication of this result is that control microglia are more able to reduce 
the levels of β-amyloid released by SH-SY5Y cells than iron-fed microglia. It should 
Page 11 of 59
ACS Paragon Plus Environment
ACS Chemical Neuroscience
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
P a g e  | 12 
 
be noted that treatment of SH-SY5Y cells with just iron had no significant effect on β-
amyloid levels (Suppl. Figure 1). 
The decreased levels of β-amyloid detected in medium of SH-SY5Y cells following 
treatment with microglial conditioned medium can either be a result of decreased 
release of β-amyloid or increased breakdown of the peptide. While we have shown 
that conditioned medium from microglia reduced APP cleavage there was no 
significant difference between control and iron-fed microglia. Therefore the difference 
we noted in β-amyloid present in the medium is more likely to be a result of altered 
breakdown. We therefore used synthetic β-amyloid to measure its breakdown by 
microglia conditioned medium. Equal amounts of β-amyloid was placed in wells and 
treated with either serum free medium, control microglia conditioned medium or iron-
fed microglia conditioned medium for 24 h. Following the assay, the levels of β-
amyloid measured were compared as a percentage to the levels detected in the 
serum free medium control as a percentage. Three different concentrations of the 
conditioned medium were tested.  β-amyloid (both Aβ1-40 and Aβ1-42) was degraded 
by the conditioned medium in direct relation to the amount of conditioned medium 
added (Figure 7C-D). At 25% and 50% concentrations conditioned medium from 
iron-fed microglia had a significantly weaker effect. The implication is that microglia 
release factors in their conditioned medium that degrade β-amyloid and iron-fed 
microglia release significantly less of these. 
Microglia release a number of factors known to degrade β-amyloid. Among these are 
insulin-degrading enzyme (IDE)42 and neprilysin43. We tested specific inhibitors of 
these enzymes to determine of the reduction in β-amyloid caused by microglial 
conditioned medium was due to the presence of these enzymes. We repeated the 
MSD assay for testing the degradation of β-amyloid by conditioned medium but 
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added either 30µM ML345 (IDE inhibitor) 44 or 10 µM thiorphan (neprilysin inhibitor) 
45 in parallel. The results show that the IDE inhibitor but not the neprilysin inhibitor 
significantly reduced the degradation of β-amyloid (both Aβ1-40 and Aβ1-42) by 
microglia conditioned medium (Figure 7E-F). This implies that IDE is the likely 
candidate protein released from microglia that degrades β-amyloid in our system. 
We verified that IDE was released by control and iron-fed microglia by collecting 
conditioned medium from microglia, concentrating it and testing for the presence of 
IDE by western blot. IDE was detected at equivalent expression levels in control and 
iron-fed microglia and was also present in the medium collected from the cells 
(Figure 7G-H). The levels of IDE in iron-fed microglial conditioned medium were 
significantly lower than for control. This supports the suggestion that iron-fed 
microglia release significantly less IDE than control microglia. 
 
Mechanism of Reduced IDE Release by Iron-fed Microglia. 
We observed no change in IDE expression in iron-fed microglia. Therefore, another 
factor must be altering the levels released. It has been reported that IDE released 
from microglia is influenced by changes in autophagy 46. Therefore we assessed 
autophagic flux in our model microglia. The expression levels of the protein LC3-II 
are a reliable indicator of the level of autophagosomes in cells 47. Inhibition of 
autophagy with bafilomycin in conjunction would then give an assessment of the 
turnover of LC3-II 48. Therefore, an increase in LC3-II levels in microglia that remains 
unaltered by bafilomycin treatment would be indicative of reduced autophagy. 
Control and iron-fed microglia were grown in serum free medium and treated either 
with 13 nM bafilomycin or the equivalent volume of methanol vehicle (20 µL). After 
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16 h protein extracts were prepared from the cells and the levels of LC3-I and LC3-II 
determined by western blot (Figure 8). Iron-fed microglia grown in serum free 
medium showed significantly higher LC3-II levels than control microglia. Bafilomycin 
significantly increased the levels of LC3-II detected in control microglia when 
compared to the methanol control but there was no such change for iron-fed 
microglia with the same treatment. The results suggest that autophagy in iron-fed 
microglia is inhibited in comparison to control microglia. 
Changes in autophagy are often associated with changes in endoplasmic reticulum 
(ER) stress. Mechanistically, this would provide a potential start point for the 
changes observed as ER stress can be induced by iron overload 49. We therefore 
examined the expression of a range of proteins that either link or are associated with 
ER stress and autophagy. These include MTOR (mammalian target of rapamycin) 
associated with down-regulation of autophagy when phosphorylated 50, EIF2a 
(eukaryotic translation initiation factor 2a) associated with increased ER stress 51, 
SCAMP5 (secretory carrier membrane protein 5) which links increased ER stress to 
decreased autophagy 52, FMRP which decreases the expression of proteins such as 
SIRT1 as a result of ER stress 53, and acetylated NF-ᴋB which is associated with 
alteration in released cytokines as a result of ER stress 54. Extracts were prepared 
from control and iron-fed microglia and applied to the western blot procedure. 
Specific antibodies were used to detect bands associated with the proteins of 
interest (Figure 9) and the bands quantitated by densitometry (Table 2). There was a 
significant increase in the level of phosphorylated MTOR, but the levels of total 
protein remained the same. This change fits with the suggestion that autophagy is 
down regulated in iron-fed microglia. Similarly, levels of phosphorylated EIF2a were 
increased with no change in the total protein. This fits with the notion that ER stress 
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is increased in iron-fed microglia. Both FMRP and SCAMP5 were increased further 
supporting these suggestions. Lastly, acetylated NF-ᴋB (p65) was increased with no 
change in total NF-ᴋB levels. This change is also associated with decreased 
autophagy through decreased SIRT-1 activity 55. 
As we have evidence that both autophagy and ER stress are altered in iron-fed 
microglia we wished to determine if inhibiting autophagy and inducing ER stress 
would cause a change in IDE release from control microglia. We therefore used 
bafilomycin to inhibit autophagy and both brefeldin A and tunicamycin to induce ER 
stress. Conditioned medium was collected from control microglia that had been 
treated overnight with these compounds and extracts were prepared from the treated 
microglia to assess cellular levels of IDE. The conditioned medium was 
concentrated, and the IDE levels were assessed by western blot (Figure 10). All 
three compounds significantly reduced the levels of IDE that could be detected in 
conditioned medium but had no effect on the cellular levels of IDE. These results 
support the notion that ER stress and consequential reduced autophagy cause 
reduced levels of IDE release by microglia. 
Lastly, to verify that the effect of autophagy inhibition and ER stress diminish the 
ability of microglia to degrade β-amyloid, the conditioned medium from the microglia 
treated with bafilomycin, brefeldin A or tunicamycin was applied to the MSD assay 
using synthetic β-amyloid. β-amyloid was treated with the conditioned medium from 
the microglia for 24 h and the levels of β-amyloid remaining were assessed. 
Treatment of the microglia with all three compounds significantly decreased the 
degradation of β-amyloid (both Aβ1-40 and Aβ1-42), indicating that reduced IDE release 
resulted in decreased β-amyloid degradation (Figure 11).  
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DISCUSSION 
Non-familial AD is the most common neurodegenerative disease and incidence 
rapidly increases with age, making the aging process the major risk factor 56. 
Therefore, understanding how brain aging impacts the incidence of AD is a major 
necessity for its possible treatment. While the exact cause of AD remains 
unresolved, the deposition of aggregates of β-amyloid is at the least a significant 
marker for its progression and at the most the causative agent 57. The true role of β-
amyloid in the pathogenesis probably lies somewhere between these extremes. 
While the formation of β-amyloid is a normal cellular consequence of the metabolic 
breakdown of APP, increasing its levels either through alterations in the metabolic 
fate of APP or increasing its extracellular survival through reduced breakdown 
directly corresponds to increased possibility of extracellular aggregates forming 58-60. 
There has been increasing discussion of the potential role of microglial aging and 
dysfunction in AD 20, 28, 61-63. However, the nature of patient tissues and even animal 
models make assessment of molecular interactions difficult, necessitating cell 
models where real time interactions can be monitored and changes assessed. Our 
model of dystrophic/senescent microglia therefore provides an opportunity for which 
there is currently little alternative. Given the issues with rodent models to reproduce 
an inherently human disease 64 we deliberately chose human cell lines for our 
approach. While different microglia “states” such as activated and primed 65 or 
phenotypes such as ramified and phagocytic can be modelled, there are no such 
models for senescent/dystrophic microglia. The major criteria for determining the 
characteristics of dystrophic microglia is based on morphological changes in tissue 
which inherently poorly translates to in vitro models 18, 35. Similarly, there is no 
universal marker that can discriminate a dystrophic microglia from any other 18. 
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Worse still is that large scale proteomics/transcriptomics based studies have failed to 
identify reproducible differences between aged microglia and controls, with each 
study listing almost incomparable data sets 66-71. The one exception to this is ferritin 
expression. Microglia express more ferritin than most cells of the brain but this is 
further elevated in dystrophic microglia and implicates that iron storage is also 
increased 22. A more objective way to assess senescence in microglia is to use the 
same criteria used for assessing general cellular senescence i.e. the 
characterization of their secretory phenotype 72. The induction of the senescence 
associated secretory phenotype (SASP) is likely to become the standard approach to 
identify senescent cells in the absence of a specific marker 73. 
We induced a senescent/dystrophic phenotype in microglia by iron overload. This 
resulted in a change in expression of ferritin and iron storage. While the high levels 
of iron used were artificial and unlikely to be encountered in vivo, they were 
employed as a means to an end and played no further role once we had induced the 
phenotype, as the high iron environment was removed from the culture system when 
analysing changes and producing conditioned medium. However, the levels of stored 
iron and the increase in ferritin levels we measured are in line with previous 
suggested increases in both iron concentrations and ferritin levels in specific brain 
regions that have previously been measured74. Of all the cell types in the brain, 
microglia show the largest increase in iron storage with age and are therefore likely 
to have much higher levels that the average for any specific brain region25. 
 
We verified the senescent/dystrophic phenotype by measuring molecules released 
by the microglia (cytokines and glutamate) 36, 75 as well as changes in protein 
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expression associated with an aged phenotype (KV1.3, SIRT-1) 37, 39. Interestingly 
age associated changes in both KV1.3 and SIRT-1 have been shown to influence 
increased cytokine release 38, 39. Other changes observed later in the study also 
support the SASP state of the iron-fed microglia. These include changes in 
autophagy and ER stress 76, 77. 
The multitude of changes we have measured in our model microglia converge on a 
general phenotype that would be expected in a senescent cell. Along with altered 
release of molecules such as cytokines, these changes included reduced ability to 
deal with stress and a failure in processes aimed at clearing away damaged proteins 
such as autophagy. 
The relation of microglia to AD has long been considered 78-81. Similar to the study of 
many neurodegenerative diseases, the study of microglia in AD has principally 
concerned the physical relation of microglia in patient brains and transgenic mice to 
pathological hallmarks such as β-amyloid deposition 82 or neuronal loss 83. The 
potential role of microglia has been suggested to be direct: causing neuronal loss 
through activation in response to β-amyloid 84, indirect: changing parameters such as 
plague load 85 or bystander: attracted to plaques without altering the pathology. 
There have been some suggestions that β-amyloid is not necessary to the 
mechanism of neuronal loss and that eliminating microglia in AD transgenic mice 
prevents neuronal loss without change to β-amyloid plaque levels 86. However, the 
most convincing evidence suggests that microglia influence clearance of β-amyloid 
due to the production of enzymes able to degrade it or by phagocytic uptake 32. 
Thus, regulation of β-amyloid clearance is the most likely physiological role of 
microglia in AD.  
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Our findings emphasize the importance of microglial proteases to the removal of β-
amyloid and how disruption of the release of enzymes like IDE could compromise 
this role. The human microglia cell line we used released IDE which in our system 
almost completely removed β-amyloid released by SH-SY5Y cells over 24 h. IDE is 
released by primary microglia but not all microglia cell lines (e.g. BV2), indicating that 
caution must be used in the choice in cell lines to model age-related microglia 
changes 87, 88. The reduced release in IDE we observed for iron-fed microglia was a 
result of reduced autophagy which has been previously observed 46, 89, but is a 
mechanism that has been poorly studied. It has been noted that changes in this 
pathway involve changes in the level of phosphorylated MTOR 89, which we also 
observed. Outside of the possible association of reduced IDE release with the 
dystrophic phenotype, we observed that both reduced autophagy and increased ER 
stress had the same effect. The implication is that any process that alters microglia 
in a similar way could also influence the levels of β-amyloid in the brain. However, 
reduced autophagy and increased ER stress are characteristics of senescence-
associated secretory phenotype 76, 77. It should also be noted that the change in IDE 
release was not due to a general failure in IDE expression in the cells as we did not 
observe any change in cellular expression. 
There has been discussion of how important reduction in β-amyloid degrading 
enzymes is to AD. There are some reports that suggest that such a reduction would 
only contribute to late stage changes 90. Of course, studies of patients don’t take into 
account preclinical changes that may play a role in disease onset. The general 
consensus is that these enzymes are extremely important and regardless of 
causality, regulating their activity may have therapeutic value 91. An additional 
consideration is the relative contributions of the different enzymes to β-amyloid 
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degradation in the brain. Our study has focused on IDE and not neprilysin because 
we found no contribution from the latter in our system, but this may not reflect the 
roles of these enzymes in AD. There has been suggestion that neprilysin is the main 
enzyme affected in AD 92 and others  suggest it might be a different enzyme 
altogether, such as angiotensin-converting enzyme 93. However, IDE is clearly 
important when considering β-amyloid degradation in the brain. First, IDE is reduced 
with age in regions associated with AD 94. Second, overexpression of IDE causes a 
significant reduction in plaque load 95. Thirdly given these enzymes are both 
released by microglia, and as the principal change may be in the SASP of microglia 
it may be a moot point exactly which enzyme is most involved.  
A final additional factor is that enzymes generated by neurones themselves and 
released extracellularly might also contribute to APP degradation. Such enzymes 
include endothelin-converting enzyme and membrane type-metalomatrix proteins 
(MMPs)96, 97. These enzymes may also be released by SH-SY5Ys. Factors from 
microglia may also influence levels of these proteins which could have also affected 
levels of β-amyloid in our system. 
We also examined other factors that could alter the generation of β-amyloid by SH-
SY5Y cells. In particular we noted that conditioned medium from microglia 
significantly reduced the formation of AICD, a C-terminal cleavage product of APP, 
but this effect was replicated when the conditioned medium was generated from iron-
fed microglia. While a change in the processing of APP could result in reduced 
release of β-amyloid by SH-SY5Y cells, and consequently the level of β-amyloid 
measured in the MSD assay, it has no bearing on the assays with synthetic β-
amyloid. Therefore, these results support the potential role of microglia in regulating 
β-amyloid levels released from cells. Destruction of microglia in mice has been 
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shown to increase plaque size 98. We also noted a significant change in the levels of 
ADAM10 expression in SH-SY5Y cells treated with conditioned medium from iron-
fed microglia, but as there was no observed change in the activity of ADAM10, the 
consequences of this altered expression are likely to be insignificant to the 
processing of APP and the subsequent levels of β-amyloid. These findings do not 
rule out other potential changes to protein expression and metabolism in SH-SY5Y 
cells, but these may or may not have any bearing on APP metabolism specifically. 
While the study on microglia-neuron interactions is hardly new, there has been little 
study of the impact of microglia on APP processing in neurons. This is surprising 
given there is significant evidence that APP processing is influenced by cytokines 
released by microglia 99-101. However, we are confident that a system of study such 
as ours will increase consideration of microglia in the study of APP.  
In summary, we have established a unique model of senescent/dystrophic microglia 
and used this to examine the role of dystrophic microglia in the turnover of β-
amyloid, a major player in AD. A comprehensive overview of our findings is 
illustrated in Figure 12. Microglia induced to take up iron show changes in molecular 
expression suggestive of changes in ER stress and autophagy. The consequence of 
these changes is the adoption of a senescence associates secretory phenotype and 
changes in the release of a variety of proteins including cytokines and enzymes like 
IDE. Decreased release of IDE results in decreased breakdown of β-amyloid 
released by neuronal cells. These findings provide a potential mechanistic insight 
into how microglial aging can contribute to the accumulation of β-amyloid and 
advance the pathology of AD. 
METHODS 
Unless otherwise stated reagents were purchased from Sigma-Aldrich. 
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Cell Culture 
The microglia cell line used in this study was the SV40 immortalised human 
microglia cell line (ABM). Cells were cultured in DMEM with 4.5 g/L glucose (LONZA) 
supplemented with 10% FBS (Labtec), and 1% pen/strep.  Cells were maintained at 
37oC and 5% CO2 in a humidified incubator. The neuronal cell line used in 
experiments was the SH-SY5Y human neuroblastoma. This cell line was grown 
under the same conditions as the microglial cell line. Images of microglia were either 
produced using a Nikon Diaphot-TMD inverted microscope (live cells) or Nikon 
Eclipse E800 microscope (stained cells). Perl’s staining was performed using a kit 
from Atom Scientific. Control and iron-fed microglial cells were plated onto cover 
slips and left overnight. They were washed in PBS and fixed in ice-cold methanol for 
5 min at -20oC. The cells were stained according to the manufacturer’s instructions 
and mounted onto slides using glycerol jelly as mounting medium. 
 
Microglia were cultured in high iron conditions to induce a senescent phenotype. The 
iron stock solution used was 25mM ferric ammonium citrate(Acros Organics) 
prepared in deionised water and filtered through a 0.22μm syringe filter (Millipore) 
Microglial cell lines were grown in medium containing in 500 µM ferric ammonium 
citrate for a minimum of two weeks. Cell lines were maintained under these 
conditions until used for experiments. Conditioned medium was produced from the 
microglia by washing them with serum free medium (DMEM) to remove excess iron 
and then growing them for 48 h in DMEM supplement with B27 without antioxidants 
(Gibco) plus 1% Penicillin and Streptomycin. The conditioned medium was collected 
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from both control and iron-fed microglia and centrifuged to remove debris and filtered 
through a 0.45 µm filter before use in further experiments. 
 
Drug treatments were for 16 h or 24 h. Brefeldin A (10mM), Bafilomycin (2μM) and 
tunicamycin (1.2mM) were prepared as stock solutions in methanol. Concentrated 
stocks of the IDE inhibitor ML345 (10.4mM) and the neprilysin inhibitor thiorphan 
(1mM) were prepared as concentrated stocks in DMSO. Synthetic β-amyloid was 
from Meso Scale Discovery. 
 
Western Blot 
Cells were lysed in PBS with 0.5% Igepal CA-630 and ‘complete’ protease inhibitor 
cocktail (Roche), sonicated 5 seconds on ice, incubated on ice for 20 min and 
centrifuged 10 000 x g for 5 min to remove insoluble membranes. Protein 
concentration was determined with a Bradford protein assay (Bio-Rad), according to 
the manufacturer’s instructions. Protein concentrations were normalized and 
samples were boiled for 5 min with 1 x Laemmli SDS-PAGE buffer. Samples were 
loaded into either a 10% or a 14% (depending on molecular weight of the protein) 
acrylamide SDS-PAGE gel, with a buffer of Tris (250 mM) + Glycine (1.92 M) + SDS 
(0.1% w/v), run at 250V and 35mA/gel for 45-60 min. Separated proteins were 
transferred to a PVDF membrane (Millipore) by a semi-dry transfer apparatus, run at 
25V and 100mA/gel for 1.5 h. Membranes were blocked in 5% w/v non-fat milk 
powder in Tris buffered saline + 0.1% Tween 20 (TBS-T) for one hour, incubated 
with primary antibody for 1-2 h or overnight, and washed 3 x 15 min in TBS-T. 
Membranes were blocked again for 10 min and incubated with horseradish 
peroxidase-conjugated secondary antibody (DAKO) for one hour. A further 3 x 15 
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min washes were performed, and the membranes developed with Luminata 
Crescendo or Luminata Forte ECL substrate (Thermo Scientific), and imaged with a 
Fusion SL CCD imaging system (Vilber Lourmat). Antibodies used in this study 
included, rabbit anti-ferritin light chain (ab69090, Abcam), rabbit anti-KV1.3 
(APC101, Alomone Labs), mouse anti-GAPDH (ab8245, Abcam), mouse anti-alpha-
tubulin (B512, Sigma), anti-APP (ab133509, Abcam), rabbit anti-ADAM10 (Millipore), 
rabbit anti-BACE1 (Cell Signalling Technology) mouse anti-SIRT1 (1F3, Cell 
Signaling Technology), rabbit anti-insulin degrading enzyme (EPR6099, Abcam), 
rabbit anti-LC3 (ab48394, Abcam), rabbit anti-MTOR (PA1-518, ThermoFisher), 
rabbit anti-phospho-MTOR (S2448, ab109268, Abcam), rabbit anti-EIF2a (Cell 
Signalling Technology), rabbit anti-phospho-eIF2a (Ser51, Cell Signalling 
Technology, rabbit anti- NF-ᴋB p65 (D14E12, Cell Signalling Technology), rabbit 
anti-acetyl-NF-ᴋB p65, (Lys310, Cell Signalling Technology), rabbit anti-FMRP 
(ab17722, Abcam) and rabbit anti-SCAMP5 (ab3432, Abcam). Densitometric 
analysis was performed on Image J. 
 
Iron Assay 
The levels of total iron in human microglia were determined using a commercial 
assay (Abcam) and following the manufacturer’s instructions. Cellular iron content 
was determined from four confluent T25 flasks and normalized to total protein 
content determined by the Bradford assay.  
 
Glutamate Assay 
Glutamate levels in conditioned medium were assessed using a commercial kit 
according to the manufacturer’s instructions (Sigma). Microglia were plated out at 
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equivalent densities and conditioned medium was generated as described above. 
After collection of the conditioned medium the microglia were lysed and protein 
concentration was measured using the Bradford assay. The glutamate 
concentrations were normalised to protein content in the lysates. 
 
ADAM10 Activity Assay 
The enzymatic activity of ADAM10 in SH-SY5Y cells was assessed using a 
commercial kit according to the manufacturer’s instructions (Anaspec). Confluent 
SH-SY5Y cells were treated with SFM or conditioned medium from microglia for 24h. 
The cells were lysed and protein concentrations were measured using the Bradford 
assay. Equivalent amounts of protein were used in the ADAM10 activity assay to 
account for differences in cell number. Readings were taken at 520nm every 5 min 
and the initial rate was calculated for each condition. 
 
Promoter Assay 
The ADAM10 promoter construct was a gift and was as previously described 102. SH-
SY5Y cells were grown in 24-well plates seeded at 5 × 104 cells/well 24 h prior to 
transfection. Transfections of the promoter construct in pGL Basic (with firefly 
luciferase activity) were performed using FuGENE HD® transfection reagent 
(Promega) as per manufacturer's instructions. To control for variation in transfection 
efficiency among replicates, promoter constructs were co-transfected with the Renilla 
luciferase vector, pRL-TK (Promega). At 24h post transfection, SH-SY5Y cells were 
harvested and firefly and Renilla luciferase chemiluminescence were measured 
using the Dual-Luciferase® Reporter Assay System (Promega) in a BMG FLUOstar 
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Omega plate reader (BMG Labtech GmbH). Luciferase activity was calculated as the 
ratio of firefly to Renilla luciferase activity. 
 
APP cleavage Luciferase reporter Assay 
The luciferase reporter assays was carried out as previously described 103. SH-SY5Y 
cells were plated out at 5 × 104 cells/well in 24 well plates in triplicate for each 
condition and left to re-attach for 18-24 h at 37oC, 5% CO2. Test wells were 
transfected with plasmids pFR-Luc (A firefly luciferase reporter construct pFR 
controlled by a synthetic promoter made of five tandem repeats of the yeast GAL4 
activation sequence followed by a minimal TATA box), APP-Gal4 (pRC-CMV vector 
containing APP695 cDNA and a Gal4-DNA binding domain fused to its C-terminal. 
Cleavage of the AICD domain with Gal-4 domain attached leads to it binding to the 
pFR vector and expressing firefly luciferase) and pRL-TK (containing Renilla 
luciferase as above) using the transfection reagent Fugene HD. Control wells were 
transfected with pFR-Luc and pRL-TK only to assess background luciferase activity. 
The cells were transfected for approximately 24 h and then treated with SFM or 
microglial conditioned medium for 24 h. After lysing and harvesting the cells firefly 
luciferase and Renilla luciferase activity were measured with the Dual-Luciferase® 
Reporter Assay System on a FLUOstar Omega plate reader. Luciferase activity was 
calculated as the ratio of firefly to Renilla luciferase activity. 
 
Proliferation Assay 
Proliferation of C8B4 microglia was assessed using the Abcam BrdU proliferation 
ELISA kit (Abcam, ab126556) according the manufacturer’s instructions. Both 
untreated and iron-fed human microglia were plated at equal density ranging from 
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2000 to 20,000 cells per well in 96 well trays. The cells were exposed to BrdU 
(bromodeoxyuridine) for 24 h prior to starting the assay. Absorbance was measured 
at 450 nm in a FLUOstar Omega plate reader following the colorimetric assay. 
 
β-Amyloid Assay 
Concentrations of β-Amyloid (both 1-40 and 1-42) present in cell culture medium 
were determined using the Meso Scale Discovery (MSD) Sector Imager S 600 
multiplex plate reader. The plate used for the analysis was the V-Plex Aβ Peptide 
Panel kit 1 (MSD). Medium was collected from SH-SY5Y cells that had been 
exposed either to conditioned medium or control medium (DMEM with B27 
supplement) as described above and filtered through a 0.22 µm filter before applying 
to the plate without dilution. Concentrations were determined by comparison to a 
standard curve for each individual β-Amyloid peptide. The values were adjusted for 
plating density by assessing the protein content of the cells used to generate the 
conditioned medium using the Bradford assay and dividing the β-Amyloid 
concentration by the protein concentration. 
 
Cytokine Assay. 
Cytokines secreted by the human microglia were also measured using the MSD 
Sector Imager S 600 multiplex plate reader. The cytokines were assessed using the 
V-PLEX Proinflammatory Panel 1 Human Kit (MSD). This kit measured IFN-γ, IL-10, 
IL-12p70, IL-13, IL-1β, IL-2, IL-4, IL-6, IL-8 and TNF-α. Conditioned medium was 
collected from control and iron-fed microglia as described above. The microglia used 
to generate the conditioned medium were lysed and their protein content was 
measured using a Bradford Assay to account for differences in cell number. 
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Statistics 
All statistics were carried out in Microsoft Excel. Statistical analyses were conducted 
using a two-tailed Student’s t test, statistical significance at p-value of < 0.05. Data 
are expressed as the mean ± standard error (S.E.). 
 
SUPPORTING INFORMATION: (A figure showing the effect of Iron on β-amyloid in 
SH-SY5Y cell medium) 
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Cytokine 
(ng/mg) 
Control  Iron-fed  
IL-8 47211.41  ± 19621.34 120271.14 ± 22992.87* 
IL-6 3393.33 ± 1501.62 14181.68 ± 2346.10* 
IL-1b 35.95 ± 12.72 115.31 ± 23.87* 
IL-13 1.05 ± 0.16 1.47 ± 0.29 
IL-10 0.03 ± 0.00 0.05 ± 0.01 
IL-2 0.05 ± 0.04 0.15 ± 0.02 
TNFα 0.88 ± 0.47 0.16 ± 0.08 
IFNγ ND ND 
IL-4 ND ND 
IL-12p70 ND ND 
 
 
Table 1 Cytokine released into conditioned medium 
Serum free conditioned medium was generated from cultured microglia over 24 h and the 
levels of cytokines assessed with the MSD ELISA system. Cytokine concentrations were 
determined by comparison to a standard curve for each cytokine. Values were the 
concentration in the medium (ng/mL) divided by the concentration of the protein in the cells 
that were used to generate the conditioned medium (mg/mL). Shown are the mean (ng/mg) 
and s.e. for four experiments. * Indicates a significant difference between control and iron-
fed (p-value <0.05). n.d. indicates not detectible due to the levels detected being below the 
level of lowest standard on the standard curve for that cytokine. 
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Protein  
(Relative value, Units) 
Control  Iron-fed  
Total mTOR  1.6 ± 0.2 1.8 ± 0.2 
Ratio p-mTor/T-mtor 1.0 ± 0.1 4.2 ± 0.7 * 
Total eIF2a 1.1 ± 0.2 1.0 ± 0.1 
Ratio p-eIF2a /T-eIF2a 1.0 ± 0.3 2.3 ± 0.3 * 
FMRP 1.0 ± 0.2 2.3 ± 0.3 * 
SCAMP-5 1.0 ± 0.2 2.4 ± 0.4 * 
Total NF-ᴋB 1.1 ± 0.2 1.0 ± 0.2 
Ratio Acetyl-NF-ᴋB/T-NF-
ᴋB 
1.0 ± 0.3 2.6 ± 0.7 * 
 
Table 2 Altered Expression of Protein in Iron-Fed microglia 
Densitometric analysis of the bands on western blots shown in Figure 10. Total levels of 
mTOR, eIF2a and NF-ᴋB were assessed as well as the ratio of the modified (p or acetyl) form 
to the total form (T). Shown are mean and s.e. for 4-8 experiments each.* Indicates a 
significant difference between control and iron-fed (p < 0.05). 
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FIGURE LEGENDS 
Figure 1 iron-fed microglia in culture 
Photomicrographs of human immortalized microglia in culture A Microglia grown in 
control conditions showed many fine process (arrows) B Microglia grown in 500 μM 
ferric ammonium citrate (iron-fed) for at least two weeks showed a loss of these 
processes.  Arrows indicated more amoeboid appearance. Scale bar = 100 µm. 
 
Figure 2 Iron and ferritin in iron-fed microglia 
Perl’s Stain is a traditional stain for the detection of iron deposits in cells. Cultured 
microglia were stained using Perl’s stain. Iron deposits appear blue following the 
procedure. A Control microglia show no obvious staining while B Iron-fed microglia 
(grown in iron for at least two weeks) show extensive blue staining in almost all cells 
(arrows). C Western blotting was used to detect ferritin in protein extracts from 
control and iron-fed microglia. GAPDH was used as loading control. D Densitometric 
analysis of ferritin expression was normalized to GAPDH levels (relative value). Iron-
fed microglia show significantly higher levels of ferritin expression (p < 0.05) when 
compared to controls. Shown are the mean and s.e. of four experiments. E The level 
of iron was detected in extracts from microglia using a commercial kit. The iron-fed 
microglia showed very high and significantly different (p < 0.05) levels of iron when 
compared to controls. Shown are the mean and s.e. of four experiments. 
 
Figure 3 Proliferation of iron-fed microglia 
The rate of proliferation of human immortalized microglia was assessed using a 
BrdU based ELISA kit. Both control and iron-fed microglia were plated into a 96 well 
plate at a range of densities and grown overnight. BrdU was then added for a further 
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16 h before the ELISA assay was used to assess incorporation levels. The level of 
incorporation was assessed by a colorimetric assay with a read out at 450 nm. Iron-
fed microglia showed no significant difference in proliferation at all plating densities 
(p > 0.05). Shown are the mean and s.e. of four separate experiments. 
 
 
Figure 4 Glutamate release and protein expression iron-fed microglia 
A The release of glutamate by human immortalized microglia was assessed with a 
commercial glutamate assay kit. Control and iron-fed microglia plated at equal 
density were grown in serum free medium for 48 h. The level of glutamate was then 
determined after collecting the medium. The protein content of the conditioning cells 
was determined in parallel. Glutamate concentration was assessed relative to the 
protein content of the cells to account for differences in cell number. Iron-fed 
microglia released significantly less glutamate than control microglia (p < 0.05). B 
Western blotting was used to assess the level of expression of KV1.3 in protein 
extracts from control and iron-fed microglia. A specific antibody was used to detect 
KV1.3 and GAPDH. C Western blotting was used to assess the level of expression 
of SIRT-1 in protein extracts from control and iron-fed microglia. A specific antibody 
was used to detect SIRT-1 and GAPDH. D Densitometric analysis of KV1.3 and 
SIRT-1. Expression was normalized to GAPDH levels (relative value). Iron-fed 
microglia show significantly higher levels of KV1.3 expression (p < 0.05) and 
significantly lower SIRT-1 expression (p < 0.05) when compared to controls. 
* indicates significant difference. Shown are the mean and s.e. of four experiments 
for all parts. 
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Figure 5 Effects of microglial conditioned medium on protein expression. 
Conditioned medium was prepared from control and iron-fed microglia. The 
conditioned medium was applied to SH-SY5Y cells for 24 h. Extracts were prepared 
from the SH-SY5Y cells along with cells that had been treated only with serum free 
medium (SFM). The extracts were applied to a PAGE gel, and the gel western 
blotted. APP, ADAM10, BACE-1 and tubulin (loading control) were detected on the 
resultant membrane with specific antibodies. Following detection, the intensity of the 
bands was assessed using densitometry. A-B. Analysis of APP expression in SH-
SY5Ys showed there was no significant (p > 0.05) effect of either control or iron-fed 
conditioned medium. The same result was seen whether the individual bands were 
quantitated together or separately. 
C-D. In contrast, treatment of SH-SY5Y cells with conditioned medium from iron-fed 
microglia (but not control) reduced the protein expression of ADAM10 significantly (p 
< 0.05) when compared to SFM. E-F.  There was no significant effect of either 
microglial conditioned medium on the expression of BACE-1 in SH-SY5Y cells. 
Shown are the mean and s.e. for four experiments each. * indicates a significant 
difference when compared to SFM. 
 
Figure 6 Investigation of microglia induced changes in ADAM10 
A The level of APP cleavage in SH-SY5Y cells was measured using a dual 
luciferase reporter assay. The assay is based upon binding of a GAL-4 DNA binding 
domain to the DNA sequence in the luciferase reporter construct. Binding is directly 
proportional to the release of the ACID domain from APP to which the GAL-4 domain 
is fused. SH-SY5Y cells transfected with the reporter constructs were treated for 24 
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h with conditioned medium from control and iron-fed microglia or with serum free 
medium (SFM). Activity measured from the firefly luciferase reporter construct 
reporting AICD release was divided by Renilla luciferase control activity (pTK) to give 
relative luciferase activity for each treatment. Conditioned medium from both control 
and iron-fed microglia caused a significant reduction in the luciferase activity 
measured (p < 0.05) compared to SFM. However, there was no significant difference 
when comparing the effect of control and iron-fed microglia conditioned medium to 
each other. 
B The level of ADAM10 promoter activity was assessed in SH-SY5Y cells. The cells 
were transiently transfected with the luciferase reporter construct carrying the 
ADAM10 promoter and the control reporter (pTK). The cells were treated with 
conditioned medium from control and iron-fed microglia for 24 h. The level of 
luciferase activity was then assessed and compared to that measured in the SFM 
control. Neither control nor iron-fed microglial conditioned medium had a significant 
(p >0.05) effect on luciferase activity. 
C The level of ADAM10 activity in SH-SY5Y cells was assessed with a commercial 
kit. The kit measured fluorescent activity following cleavage of an ADAM10 substrate 
by ADAM10 present in extracts from the cells. Extracts were prepared from SH-
SY5Y cells treated for 24 h with conditioned medium from control or iron-fed 
microglia or SFM. Fluorescence was measured at 520 nm in a plate reader following 
application of extract to the assay. The values were adjusted to the protein 
concentration of the extracts. Treatment of SH-SY5Y cells with microglia conditioned 
medium had no significant effect (p > 0.05) on measured ADAM10 activity. 
D-E FMRP is translation inhibitor known to influence protein expression of ADAM10. 
We measured FMRP expression in protein extracts from SH-SY5Y cells by western 
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blot. SH-SY5Y cells were treated with conditioned medium from control and iron-fed 
microglia or SFM. After 24 h protein extracts were prepared from the SH-SY5Y cells 
and applied to the western blot procedure. FMRP and tubulin (loading control) were 
detected with specific antibodies and the band intensity after chemiluminescence 
detection assessed with densitometry. Conditioned medium from iron-fed microglia 
but not control microglia had significant effect on FMRP detected in SH-SY5Y cells 
(p < 0.05), greatly increasing the level detected.  
Shown are the mean and s.e. for four experiments in all cases. * indicates a 
significant difference when compared to SFM. 
 
Figure 7 Microglia degradation of β-amyloid 
We used an MSD Sector Imager to measure the levels of β-amyloid in culture 
medium. The multiplex MSD assay measured both Aβ1-40 and Aβ1-42 simultaneously 
in the same experiments. 
A-B SH-SY5Y cells were treated with conditioned medium from control and iron-fed 
microglia. The levels of β-amyloid released after 24 h were assessed and compared 
to that of SH-SY5Y cells grown in serum free medium alone (SFM). The levels of 
both Aβ1-40 and Aβ1-42 were significantly (p < 0.05) reduced after either treatment. 
However, the levels of both peptides were significantly higher when SH-SY5Y cells 
were treated with medium from iron-fed microglia than they were when treated with 
medium from control microglia. 
C-D Synthetic Aβ1-40 and Aβ1-42 were treated with conditioned medium from control 
and iron-fed microglia or SFM for 24 h. The conditioned medium was diluted with 
SFM. After this time the levels of β-amyloid remaining were assessed with the MSD 
assay. In the SFM controls 904 ± 141 ng/mL Aβ1-40 and 157 ± 27 ng/mL Aβ1-42 were 
Page 35 of 59
ACS Paragon Plus Environment
ACS Chemical Neuroscience
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
P a g e  | 36 
 
detected. The amount remaining in the conditioned medium treated wells is shown 
as a percentage of these values. At both 50% and 25% conditioned medium there 
was significantly more Aβ1-40 and Aβ1-42 remaining under iron-fed conditions than 
control (p < 0.05) implying that conditioned medium from iron-fed microglia degraded 
both forms of β-amyloid less than control microglial conditioned medium. 
E-F The experiment with synthetic Aβ1-40 and Aβ1-42 was repeated but with the 
addition of enzyme inhibitors. Aβ1-40 and Aβ1-42 were treated with conditioned 
medium from control and iron-fed microglia with the addition for either DMSO 
vehicle, IDE inhibitor or neprylisin (NEP) inhibitor. After 24 h the levels of Aβ1-40 and 
Aβ1-42 remaining were assessed with the MSD assay. In the SFM controls 3715 ± 
385 ng/mL Aβ1-40 and 246 ± 42 ng/mL Aβ1-42 were detected. Compared to the DMSO 
control, the NEP inhibitor had no significant effect on the levels detected for either 
control or iron-fed conditioned while the IDE inhibitor significantly reduced 
degradation of both Aβ1-40 and Aβ1-42 (p < 0.05). 
G-H The levels of IDE were measured in both control and iron fed microglia and also 
in the conditioned medium generated from these cells. The relative levels of IDE 
were measured using western blotting and detection with a specific antibody. 
GAPDH was measured as a control for loading of the cell lysates. The conditioned 
media from the microglia were concentrated 10-fold with a 30kDa centrifugal filter 
(Sartorius) to increase chances of detection. After western blotting the detected 
bands were densitometrically quantitated. The levels of IDE in the cells were not 
significantly different between control and iron-fed microglia while that released into 
the medium was significantly (p < 0.05) reduced for iron-fed microglia. 
For all sections shown are the mean and s.e. for at least four independent 
experiments. * indicates a significant different between treatment and control. † 
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indicated a significant difference between treatments with conditioned medium from 
control and iron-fed microglia. 
 
 
Figure 8 Autophagy in iron-fed microglia 
The levels of LC3-II were determined in human microglia by western blot. Control 
and iron-fed microglia were grown in serum free medium (SFM) and treated either 
with 13 nM bafilomycin (Bafilo) or the equivalent volume of methanol (20 µL, 0.67% 
of total volume). After 16 h protein extracts were prepared from the cells and applied 
to a 14% PAGE gel. After transfer to a membrane the presence of LC3-II and 
GAPDH (loading control) were detected with specific antibodies. After 
chemiluminescent detection to visualize the bands (upper panel) the intensity of the 
bands was assessed with densitometry. Iron-fed cells grown in SFM showed 
significantly higher levels of LC3-II than control microglia (p < 0.05). Treatment with 
bafilomycin significantly increased the levels of LC3-II for control microglia but not for 
iron-fed microglia. Shown are the mean and s.e. for seven experiments. * indicates a 
significant difference between treatment and methanol control. † indicated a 
significant difference between control and iron-fed microglia. 
 
Figure 9 Expression of proteins related to autophagy and ER stress 
Protein extracts were prepared from control and iron-fed microglia. Western blotting 
and immunodetection were used to assess the level of expression of a range of 
proteins. These proteins were A phosphorylated-MTOR (p-MTOR) and total MTOR 
(T-MTOR), B phosphorylated-EIF2a (p- EIF2a) and total EIF2a (T- EIF2a), C FMRP, 
D SCAMP5 and E acetyl-NF-ᴋB and total NF-ᴋB (T-NF-ᴋB). In each case GAPDH 
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was also analysed to ensure equal loading of the samples. Quantitation appears in 
Table 2. 
 
Figure 10 Autophagy, ER stress and IDE release 
The levels of IDE were measured in cell extracts from control microglia with and 
without treatment with either with 13 nM bafilomycin, 0.1 µg/mL brefeldin A, or 1.0 
µg/mL tunicamycin. The treatments were for 16 h and after that time conditioned 
medium generated from these cells was collected and protein extracts made from 
the cells. The relative levels of IDE were measured using western blot and detection 
with a specific antibody GAPDH was measured as a control for loading of the cell 
lysates. The conditioned media from the microglia were concentrated 10 fold to 
increase chances of detection. After western blot the detected bands were 
densitometrically quantitated. None of the treatments increased IDE levels in the 
microglia but all treatments caused a significant decrease (p < 0.05) in IDE detected 
in the medium when compared to the control. Shown are the mean and s.e. from 
seven independent experiments. 
 
Figure 11 Autophagy, ER stress and β-amyloid 
Synthetic Aβ1-40 and Aβ1-42 were treated with conditioned medium from control 
microglia treated either with 13 nM bafilomycin, 100 ng/mL brefeldin A, 1.0 µg/mL 
tunicamycin or SFM alone for 16 h. After this time the levels of β-amyloid remaining 
were assessed with the MSD assay. In the SFM controls 3326 ± 240 ng/mL Aβ1-40 
and 231 ± 10 ng/mL Aβ1-42 were detected.  All three treatments significantly 
increased (p < 0.05) the level of Aβ1-40 and Aβ1-42 detected when compared to control 
microglia conditioned medium. Shown are the mean and s.e. for four experiments. 
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Figure 12 Model of Dystrophic Microglial induced increase in β-amyloid 
A summary figure illustrating the changes we have observed in this study. Excess 
uptake of iron by microglia induces a dystrophic-like phenotype illustrated by 
changes in Ferritin expression and iron storage. Increased cellular iron also 
increases the labile iron pool with the consequence of increased oxidative events 
which are known to induce ER stress. The consequence of induced ER stress is 
changes in markers such as SCAMP5 and EIF2a and altering protein translation 
through FMRP. One consequence of induced action of FMRP is the decreased 
expression of the deacetylase SIRT-1 resulting in higher levels of acetylated-NF-ᴋB. 
This change is known to result in increased release of pro-inflammatory cytokines 
indicating a switch in the secretory phenotype to one associated with cell 
senescence. Decreased SIRT1 activity is also associated with increased 
phosphorylation of MTOR, resulting in reduced autophagy. Decreased autophagy 
causes an increase in the levels of LC3-II by reduction in its turnover. It also results 
in a decrease in the secretion of proteins that include IDE. Reduced IDE then results 
in increased extracellular levels of β-amyloid. 
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